Title:
抗EGFR抗体の凍結乾燥製剤
Document Type and Number:
Japanese Patent JP2009540015
Kind Code:
A
Abstract:
In one embodiment, the present invention provides a stable lyophilized formulation comprising an anti-EGFR antibody, preferably cetuximab; lactobionic acid; and a buffer, preferably histidine. In one preferred embodiment, the present invention provides a stable lyophilized formulation comprising about 50 mg/mL to about 140 mg/mL of ERBITUX?, about 0.125% lactobionic acid, about 25 mM histidine buffer at a pH of about 6.0, about 0.005% Tween 80, and about 1.875% glycine.
Inventors:
Agarked, Mira
Srivastava, Alvind
Goldstein, Joel
Srivastava, Alvind
Goldstein, Joel
Application Number:
JP2009515628A
Publication Date:
November 19, 2009
Filing Date:
June 13, 2007
Export Citation:
Assignee:
Imclone LLC
International Classes:
A61K39/395; A61K9/08; A61K9/19; A61K47/10; A61K47/12; A61K47/18; A61K47/26; A61K47/34; A61P35/00; A61P35/04
Attorney, Agent or Firm:
Kyousei Tamura
Samejima Mutsumi
Masahiro Nitta
Shoichi Okuyama
Arihara Koichi
Matsushima Tetsuo
Hidefumi Kawamura
Naomi Yoshida
Ayako Nakamura
Masayuki Okamoto
Fukagawa Eri
Satoshi Morimoto
Samejima Mutsumi
Masahiro Nitta
Shoichi Okuyama
Arihara Koichi
Matsushima Tetsuo
Hidefumi Kawamura
Naomi Yoshida
Ayako Nakamura
Masayuki Okamoto
Fukagawa Eri
Satoshi Morimoto